Published in World J Gastroenterol on July 28, 2016
Initiation and Maintenance of Gastric Cancer: A Focus on CD44 Variant Isoforms and Cancer Stem Cells. Cell Mol Gastroenterol Hepatol (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Dendritic cells and the control of immunity. Nature (1998) 56.54
Global cancer statistics, 2012. CA Cancer J Clin (2015) 53.52
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Pathogen recognition and innate immunity. Cell (2006) 44.14
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54
Signatures of mutational processes in human cancer. Nature (2013) 21.63
Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med (2003) 16.62
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
Macrophage diversity enhances tumor progression and metastasis. Cell (2010) 13.41
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08
Comprehensive molecular characterization of gastric adenocarcinoma. Nature (2014) 11.93
Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet (2014) 8.59
Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res (2006) 8.21
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res (2014) 8.11
Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity (2014) 7.26
Natural innate and adaptive immunity to cancer. Annu Rev Immunol (2011) 7.09
Immunogenic cell death in cancer therapy. Annu Rev Immunol (2012) 6.59
The concept of immunological surveillance. Prog Exp Tumor Res (1970) 4.76
Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature (2012) 4.41
Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell (2015) 4.16
Pattern recognition receptors and control of adaptive immunity. Immunol Rev (2009) 3.91
Antitumor immunity. A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection. Science (2015) 3.35
The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov (2014) 3.32
Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem (2006) 3.24
B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. Blood (2010) 3.21
Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol (2010) 3.03
The immune score as a new possible approach for the classification of cancer. J Transl Med (2012) 2.79
New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. Curr Opin Immunol (2014) 2.47
Immune modulation in cancer with antibodies. Annu Rev Med (2013) 2.23
Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer (2000) 2.09
Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability. Immunity (2016) 1.96
Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med (2015) 1.93
Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest (2015) 1.92
Distinctive patterns of gene expression in premalignant gastric mucosa and gastric cancer. Cancer Res (2003) 1.88
A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis. Cancer Cell (2014) 1.83
Natural immunity to cancer in humans. Curr Opin Immunol (2010) 1.69
Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.68
Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest (2015) 1.67
Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer. Br J Cancer (2008) 1.62
HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene (2008) 1.59
Perforin pores in the endosomal membrane trigger the release of endocytosed granzyme B into the cytosol of target cells. Nat Immunol (2011) 1.57
Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiol Biomarkers Prev (2014) 1.56
Tumour-infiltrating lymphocytes in colorectal cancer with microsatellite instability are activated and cytotoxic. Br J Surg (2004) 1.49
Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book (2015) 1.34
Epstein-Barr virus associated gastric carcinoma: epidemiological and clinicopathological features. Cancer Sci (2008) 1.31
Prognostic and predictive values of the immunoscore in patients with rectal cancer. Clin Cancer Res (2014) 1.29
Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol (2015) 1.22
Novel mechanisms of EBV-induced oncogenesis. Curr Opin Virol (2012) 1.19
Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. Clin Cancer Res (2010) 1.14
Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma. Oncotarget (2016) 1.13
Tumor microenvironment and immune escape. Surg Oncol Clin N Am (2007) 1.12
Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. J Clin Invest (2015) 1.07
Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut (2016) 1.06
Basic principles of tumor-associated regulatory T cell biology. Trends Immunol (2012) 1.05
Intratumour T cells, their activation status and survival in gastric carcinomas characterised for microsatellite instability and Epstein-Barr virus infection. Virchows Arch (2005) 1.02
Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors. Int J Clin Exp Pathol (2015) 1.00
Prognostic implications of tumor-infiltrating FoxP3+ regulatory T cells and CD8+ cytotoxic T cells in microsatellite-unstable gastric cancers. Hum Pathol (2013) 1.00
Enhancing immunotherapy using chemotherapy and radiation to modify the tumor microenvironment. Oncoimmunology (2013) 0.98
Dendritic cell and macrophage infiltration in microsatellite-unstable and microsatellite-stable colorectal cancer. Fam Cancer (2011) 0.97
Immunotherapy in gastric cancer. World J Gastroenterol (2014) 0.96
A signature predicting poor prognosis in gastric and ovarian cancer represents a coordinated macrophage and stromal response. Clin Cancer Res (2014) 0.95
Increased frequency of antigen-specific CD8(+) cytotoxic T lymphocytes infiltrating an Epstein-Barr virus-associated gastric carcinoma. J Clin Invest (1999) 0.94
Programmed Death-1 Ligand-1 (PDL1) Expression Is Associated with the Prognosis of Patients with Stage II/III Gastric Cancer. Anticancer Res (2015) 0.90
Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations. J Gastrointest Oncol (2015) 0.89
The expression status and prognostic significance of programmed cell death 1 ligand 1 in gastrointestinal tract cancer: a systematic review and meta-analysis. Onco Targets Ther (2015) 0.89
Anti program death-1/anti program death-ligand 1 in digestive cancers. World J Gastrointest Oncol (2015) 0.88
Memory CD8+ T cell differentiation in viral infection: a cell for all seasons. World J Gastroenterol (2007) 0.87
Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer. Clin Cancer Res (2015) 0.86
Immunotherapy for Gastric Cancer: A Focus on Immune Checkpoints. Target Oncol (2016) 0.85
Polarized CD163+ tumor-associated macrophages are associated with increased angiogenesis and CXCL12 expression in gastric cancer. Clin Res Hepatol Gastroenterol (2015) 0.85
Macrophage Infiltration Induces Gastric Cancer Invasiveness by Activating the β-Catenin Pathway. PLoS One (2015) 0.84
Efficient and reproducible generation of tumour-infiltrating lymphocytes for renal cell carcinoma. Br J Cancer (2015) 0.83
Tumor associated macrophage: a review on the phenotypes, traits and functions. Iran J Cancer Prev (2014) 0.83
Strong Prognostic Value of Microsatellite Instability in Intestinal Type Non-cardia Gastric Cancer. Ann Surg Oncol (2015) 0.83
Inflammation in gastric adenocarcinoma of the cardia: how do EBV infection, Her2 amplification and cancer progression influence tumor-infiltrating lymphocytes? Virchows Arch (2011) 0.83
Tumor-infiltrating lymphocytes predict cutaneous melanoma survival. Melanoma Res (2015) 0.81
Tumor Microenvironment and Immunotherapy: The Whole Picture Is Better Than a Glimpse. Immunity (2015) 0.81
Cancer-immune equilibrium: questions unanswered. Cancer Microenviron (2011) 0.78